Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial재조합 인터페론 무장 융합 단백질 백신(V-01)을 사용한 SARS-CoV-2에 대한 이종 부스팅의 효능: 무작위, 이중 맹검 및 위약 대조 3상 시험Clinical Trial Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] adverse event antibody assigned booster clinical trial common adverse event conducted COVID-19 vaccine COVID-19 vaccines dose double-blind dramatic increase Efficacy elicit eligible fatigue Fever fusion protein groups headache healthy Heterologous heterologous boosting Humoral immunity Identifier Immunity inactivated Inactivated vaccine Inactivated Vaccines Inc injection injection site intention-to-treat principle Malaysia Mild-to-moderate Neutralizing Neutralizing antibodies occurred Older omicron Omicron variant over Pain participant Participants Placebo placebo-controlled primary endpoint Randomized Randomly receive regimen robust Safe SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Events subunit Subunit vaccine Subunit vaccine. Surveillance symptomatic SARS-CoV-2 infection the epidemic titre Trial Trial registration V-01 Vaccine vaccine efficacy variant virus-neutralizing antibodies was measured were assessed [DOI] 10.1080/22221751.2022.2088406 PMC 바로가기 [Article Type] Clinical Trial
A case-case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variantsDelta 및 Omicron 변종에 감염된 백신 접종자의 폐렴 및 바이러스 부하 예방에 대한 중국산 COVID-19 백신의 1차 및 추가 접종 효과에 대한 사례 연구Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] administration age analysed association booster booster dose booster immunization calculate case study case-case study COVID-19 COVID-19 outbreak COVID-19 pneumonia COVID-19 vaccine Ct value Ct values Delta determine eligible evaluated immunization Infection infections less Logistic regression no difference no differences Odds ratio Odds ratios omicron pace Pneumonia real-world study. recipient reduced reduction SARS-CoV-2 viral load vaccination Vaccination Status variant Viral load [DOI] 10.1080/22221751.2022.2103455 PMC 바로가기 [Article Type] Article
The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis후속 SARS-CoV-2 감염에 대한 자연 획득 항체의 보호: 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-12-012022-09-12 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI Acquired Against analyses analysis antibody asymptomatic infection conducted COVID-19 COVID-19 case COVID-19 infection COVID-19 vaccination Efficacy eligible General population HCWs Health care worker incidence rate individual Infection Meta-analysis Naturally naturally acquired antibody naturally acquired immunity Newcastle-Ottawa Scale NOS Older outcome Population programming protection provided reduce Registration Reinfection reinfection. review risk SARS-CoV-2 SARS-COV-2 infection searched seropositive significant difference significantly specific antibody subsequent symptomatic was used [DOI] 10.1080/22221751.2022.2046446 PMC 바로가기 [Article Type] Meta-Analysis
Assessing the transition of COVID-19 burden towards the young population while vaccines are rolled out in China중국에서 백신이 출시되는 동안 젊은 인구에 대한 COVID-19 부담의 전환 평가Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] absence Admissions age Assessing cause children China Chinese coronavirus disease Coronavirus disease 2019 Coverage COVID-19 deaths decrease Delta delta variant disease Effectiveness effort eligible Epidemics fatality groups highlight Hospitalization hospitalizations incidence include individual Infants Infection intensive care lineages novel Novel coronavirus novel coronavirus disease Novel coronavirus disease 2019 Older age over SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 transmission symptomatic infection symptomatic infections target population transition transition of disease burden Transmission triggered vaccinated against COVID-19 vaccination vaccination. Vaccine widespread [DOI] 10.1080/22221751.2022.2063073 PMC 바로가기 [Article Type] Article
Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort studyArticle Published on 2022-11-032022-11-16 Journal: Scientific Reports [Category] SARS, 변종, [키워드] Ad26.COV2.S vaccine Alpha Apulia calculate ChAdOx1-S Cohort combined use conducted COVID-19 COVID-19 infection COVID-19 infections COVID-19 vaccination COVID-19 vaccination programme Cox regression model death deaths Delta variants dominant Effect Effectiveness Effects Electronic health record eligible estimate hazard ratio Hospital admission hospitalisation infections Italy mRNA-1273 of BNT162b2 Older outcome positive Protective reduced retrospective cohort study SARS-CoV-2 SARS-CoV-2 infections study period subject vaccination Vaccine variant variants waned were used yielding [DOI] 10.1038/s41598-022-23235-4 PMC 바로가기
Children, adolescents, and young adults hospitalized with COVID-19 and diabetes in summer 2021Article Published on 2022-11-012022-11-16 Journal: Pediatric diabetes [Category] SARS, 변종, [키워드] adults hospitalized B.1.617.2 children Clinical characteristics collected collected data COVID-19 COVID-19 vaccination Delta described diabete diabetes Diabetic diagnosed eligible Epidemiology highlight hospital Hospitalized ICU admission incidence information Patient patients patients hospitalized pediatrics. Pneumonia presenting Prevent required retrospective SARS-COV-2 infection Type variant with COVID-19 [DOI] 10.1111/pedi.13396 PMC 바로가기
Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in QatarArticle Published on 2022-11-012022-11-15 Journal: International Journal of Infectious Diseases [Category] SARS, 진단, [키워드] 95% confidence interval adjusted odds ratio Analysis BA.2 case-control study conducted Control control group controls COVID-19 COVID-19 severity Critical Disease progression drug Effectiveness eligible Epidemiology Evidence fatal COVID-19 food form high-risk patient higher risk incidence individual Mild-to-moderate neutralizing antibody occurred omicron Patient progression protective effect receive reducing SARS-CoV-2 Sotrovimab Sotrovimab. study period Subgroup analysis subgroup of patient Treatment treatment group United State [DOI] 10.1016/j.ijid.2022.09.023 PMC 바로가기
Challenges of vaccination and herd immunity in COVID-19 and management strategiesArticle Published on 2022-11-012022-11-16 Journal: The clinical respiratory journal [Category] SARS, 변종, [키워드] acute respiratory syndrome caused challenge contagious coronavirus Coronavirus disease 2019 country COVID-19 COVID-19 vaccination COVID-19 vaccine Critical death Defense effective eligible help herd immunity Hospitalization Immunity management mutant Outbreaks prevention PROTECT reduce reducing risk SARS-CoV-2 SARS-CoV-2 variant severe disease Spread susceptible the disease vaccination vaccination. variants viral disease virus [DOI] 10.1111/crj.13543 PMC 바로가기
Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020-March 2022Article Published on 2022-11-012022-11-15 Journal: Emerging Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome administration age antibody Area caused children collected coronavirus coronavirus disease COVID-19 COVID-19 cases Delta diagnostic test Effect eligible Epidemiology Immunity incidence Infection infections Japan omicron population level receive reported respiratory infections SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 seroprevalence seropositive Seroprevalence severe acute respiratory syndrome coronavirus 2 Spread the epidemic the SARS-CoV-2 Tokyo vaccination vaccination rate Vaccine vaccine-preventable diseases variants viruses zoonoses zoonoses. [DOI] 10.3201/eid2811.221127 PMC 바로가기
Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [ComirnatyⓇ])Article Published on 2022-11-012022-11-15 Journal: International Journal of Infectious Diseases [Category] SARS, 진단, [키워드] acute exacerbation Adverse Adverse reaction Asthma BNT162b2 center Control COVID-19 vaccine dose effective eligible eosinophilia eosinophils Hospitalization individuals life-threatening Messenger RNA Patient Pfizer-BioNTech prevention receiving repeated risk factor SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccine, Acute asthma exacerbation sensitization Sensitization. the patient the SARS-CoV-2 vaccination Vaccine [DOI] 10.1016/j.ijid.2022.09.019 PMC 바로가기